Syn-Coll
Palmitoyl Tripeptide-5
Syn-Coll (Palmitoyl Tripeptide-5) is a healing & recovery research compound. TGF-beta-mimetic lipopeptide — triggers collagen I/III synthesis in dermal fibroblasts.
Syn-Coll quick facts
| Reported research dose | Topical, as directed |
| Route | Topical |
| Frequency | 1-2x Daily (topical) |
| Half-life | N/A (topical) |
| Forms | Topical |
| Evidence level | Cosmetic/topical |
Collagen-stimulating topical — the firming counterpart to the wrinkle-relaxers.
How Syn-Coll works
TGF-beta-mimetic lipopeptide — triggers collagen I/III synthesis in dermal fibroblasts.
Proposed benefits
Collagen stimulation and wrinkle reduction (cosmetic).
Where to get Syn-Coll
See vetted vendors for Syn-Coll →The evidence for Syn-Coll
Graded by what exists behind each claim.
✅ Clinically validated
- Manufacturer-sponsored topical studies report improvements in wrinkle depth and skin smoothness. Independent replication is essentially absent — the same structural weakness that runs through the whole cosmeceutical peptide category, where the supplier is also the researcher.
📊 Correlative data
- Used in anti-ageing formulations, often alongside Matrixyl. Reported experience is gradual and hard to isolate from co-formulated actives.
🧪 Theoretical / extrapolated
- Palmitoyl tripeptide-5, designed to mimic thrombospondin-1 and so activate latent TGF-β — the master regulator of collagen synthesis.
- Working through TGF-β activation is a genuinely different route from Matrixyl's fragment-signaling, and mechanistically the more powerful lever. It is also why the same pathway is implicated in fibrosis, which is worth knowing even if topical doses are nowhere near that.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Syn-Coll actually does
Syn-Coll is the trade name for palmitoyl tripeptide-5, and the first thing worth saying about it is what the regulatory definition actually contains. The Cosmetic Ingredient Review defines the ingredient as the reaction product of palmitic acid with a three-residue peptide containing lysine and valine CIR Expert Panel (Cosmetic Ingredient Review) 2012. That is a statement of composition, not of sequence. Two lysines and a valine can be assembled as Lys-Val-Lys, Lys-Lys-Val or Val-Lys-Lys; all three have the same formula, the same mass and the same isoelectric point, and the definition the ingredient is registered under does not choose between them. Trade material is described as Lys-Val-Lys, and the chemistry below assumes it, but the official record does not require it.
Computed from that sequence: the free tripeptide is 373.49 Da with an isoelectric point of 10.81 and a net charge near +1.94 at blood pH — two lysines and a free N-terminus make it one of the more cationic peptides in this class. Palmitoylation brings it to 611.90 Da and, as with every N-acylated peptide here, removes about one unit of positive charge by converting the terminal ammonium into an amide.
The mechanism claim, and where it stops matching the literature. Syn-Coll is sold as a mimic of thrombospondin-1, working by activating latent transforming growth factor beta — the master switch for collagen synthesis. Thrombospondin-1 really does do this, and the molecular detail is worked out to the level of the residues involved. The activation sequence of thrombospondin-1 is KRFK, and it works by binding the sequence LSKL near the amino terminus of the latency-associated peptide, so that the latency-associated peptide can no longer re-form the inactive complex with TGF-beta Ribeiro 1999. That is the mechanism, named to the letter.
Now compare the strings. The active sequence is Lys-Arg-Phe-Lys. This ingredient is Lys-Val-Lys. It shares the two lysines. It has no arginine and no phenylalanine, and it is one residue shorter. A guanidinium group and an aromatic ring are not decorative in a protein-protein interaction; they are usually the interaction. The claim that this tripeptide reproduces the thrombospondin-1 activation event therefore rests on a similarity that the primary literature does not support, and no published experiment has ever put Lys-Val-Lys into the assay that defined Lys-Arg-Phe-Lys.
What is left is not nothing. A dicationic amphiphile with a C16 tail behaves like the other palmitoyl lipopeptides in this family — it self-assembles, it binds anionic surfaces, and it partitions into stratum corneum lipid Castelletto 2013. Any of those could plausibly produce a measurable cosmetic change. None of them is TGF-beta activation, and the difference matters because TGF-beta activation is the part that carries both the promise and the risk.
Cell, rodent, human — and where it stops
The mechanism’s own evidence chain is excellent — and every step of it is about thrombospondin-1, not about this ingredient.
Genetics, in mice. Thrombospondin-1 null mice and TGF-beta1 null mice show strikingly similar histological abnormalities across nine organ systems; a peptide that blocks thrombospondin-mediated activation reproduced the lung and pancreatic pathology in wild-type pups, and a thrombospondin-derived peptide pushed those abnormalities back toward wild type Crawford 1998. That is about as strong as a causal argument gets in vivo.
Topically, on a wound, in mice — and this is the step closest to a cosmetic application. Thrombospondin-1-deficient mice heal abnormally, with persistent granulation tissue, reduced collagen deposition and roughly twice the microvessel number of wild-type animals at day 10. Applying either thrombospondin-1 or the KRFK peptide topically restored the wild-type repair pattern Nor 2005. So a short thrombospondin-derived peptide, applied to skin, changes tissue behavior in a mammal. That is a genuine and underquoted result. It was obtained with KRFK.
In fibroblasts, with a number. Thrombospondin-1 promoted fibroblast-mediated collagen gel contraction, and active TGF-beta1 in the treated samples was 3.30-fold higher than control; implanted thrombospondin-soaked collagen sponges increased fibroblast numbers in rats by day 7 Sakai 2003. Note what the read-out is: gel contraction. Activating latent TGF-beta in dermis does not produce smooth new collagen, it produces the contractile fibroblast phenotype that closes wounds and makes scars.
And for palmitoyl tripeptide-5 itself: zero. No indexed cell study, no animal study, no controlled human trial. It appears in the regulatory record as a registered cosmetic ingredient with frequency-of-use data CIR Expert Panel (Cosmetic Ingredient Review) 2012 and in surveys of what is actually in marketed products Resende 2021. The efficacy claims come from supplier-run, unblinded studies that are not indexed in the biomedical literature, which is the same structural weakness the reviews of topical peptides describe across this whole category Gorouhi 2009.
The obstacle, and the arithmetic on this page comes out the opposite way to the follicle peptides. 611.90 Da is over the 500 Da rule of thumb for stratum corneum Bos 2000, and peptide permeability is the standing unaddressed problem of the field Mortazavi 2022. Worse here, the target concentration is high rather than low. Competing at a protein-protein interface — which is what mimicking KRFK would mean — is a micromolar business, not a picomolar one. One micromolar of a 611.90 Da molecule is 0.61 µg/mL; the papillary dermis under a 400 cm² face, at 0.5 mm depth, is about 20 mL of tissue, so reaching 1 µM there requires roughly 12 µg delivered into the dermis. A milliliter of serum at 0.005% contains 50 µg of peptide in total, so the required delivery efficiency is about 24% — and the one permeation study of a comparable palmitoylated peptide in this cohort recovered a small percentage in dermis and nothing at all in the receptor fluid Choi 2014. On this page the barrier is the binding constraint, and it is off by more than an order of magnitude.
Syn-Coll pharmacokinetics — how much of it actually gets in
What degrades it. Skin proteases. The palmitoyl amide blocks aminopeptidase attack at the N-terminus, which measurably extends survival for this class in skin Choi 2014, but a Lys-Val bond and a free C-terminal lysine remain substrates. Trypsin-like enzymes cleave after lysine, and a peptide that is two-thirds lysine offers two such sites. No degradation rate has been measured for this compound in any tissue.
The barrier. 611.90 Da, against a 500 Da threshold Bos 2000. There is no permeation measurement for palmitoyl tripeptide-5 in any skin model — not human, not porcine, not murine, not a reconstructed epidermis. Every statement about how much of it gets in is an inference from other molecules.
The exposure, bounded. At 2 mg/cm² of product and a formulation level of 0.005%, a 400 cm² face receives about 40 µg of peptide per application. Twice a day for 12 weeks is roughly 6.7 mg in total. The whole question is what fraction of that ever reaches a fibroblast, and the answer for this specific molecule has never been measured.
Systemically, there is nothing to discuss and that is the useful conclusion. Even total absorption of a milligram-scale topical dose of a peptide that is cleaved by plasma peptidases within minutes gives no meaningful circulating exposure. There is no oral, injected or infused pharmacokinetic study of this molecule in any species, so any systemic claim about it — in either direction — is unsupported.
What would have to be true, and how you would know it was not
What to watch. Wrinkle depth and skin firmness, measured the same way twice: a fixed-lighting, fixed-distance photograph of the nasolabial fold and the crow’s feet at rest, and a cutometer reading of elasticity from a marked cheek site, at week 0, week 8 and week 16. Firmness is the claim this ingredient makes, so firmness is the number to take.
How long before it means anything. Sixteen weeks. If the mechanism were real it would work through fibroblast matrix output, which is a months-long process; anything visible in three weeks is hydration or light.
What will fool you. Co-formulation. This ingredient is usually sold beside a collagen-fragment peptide, and the two are credited jointly for whatever happens. The second trap is the photograph: nasolabial shadow depends on head angle to within a few degrees, which is why the fixed-distance, fixed-lighting discipline is the whole measurement.
Prediction 1, the sequence test, and it decides everything else. Put Lys-Val-Lys and Lys-Arg-Phe-Lys side by side in the assay that defined the activation sequence — binding to the latency-associated peptide, and release of active TGF-beta Ribeiro 1999. The prediction here is that Lys-Val-Lys does nothing in that assay. If it does nothing, then whatever this ingredient does to skin, it is not thrombospondin mimicry, and the category needs a different explanation.
Prediction 2, and it is the argument this page is proudest of. Genuine activation of latent TGF-beta in dermis produces contractile fibroblasts and gel contraction, with active TGF-beta1 rising several-fold Sakai 2003, and the same axis drives hypertrophic scarring. Two decades of wide cosmetic use have produced no reports of skin tightening in the pathological sense, no contracture, no hypertrophic response. Read that carefully: on this mechanism, the clean safety record is evidence that the mechanism is not running at cosmetic concentrations. A compound cannot claim a fibrogenic master switch as its mechanism and a total absence of fibrogenic effects as its safety profile. One of the two claims has to give, and the arithmetic above says it is the first.
Prediction 3, falsifiable in the other direction. If someone delivers this peptide past the barrier — microneedling, iontophoresis, a liposomal carrier — and it is a real TGF-beta activator, then the risk profile changes with the delivery, and the first sign would be firm, raised, slow-to-settle skin at the treated site rather than a smoother one. Anybody combining this ingredient with a delivery device is running that experiment without a control.
What nobody has tested yet
1. The one experiment that would settle the mechanism has never been run. Lys-Val-Lys against Lys-Arg-Phe-Lys in the latency-associated-peptide binding and TGF-beta activation assays Ribeiro 1999. Both peptides are trivial to synthesize, the assay is twenty-seven years old, and the ingredient has been sold on the comparison for two decades without anybody making it.
2. Nobody has published the sequence with authority. The regulatory definition specifies composition, not order CIR Expert Panel (Cosmetic Ingredient Review) 2012. An amino-acid sequencing run on commercial material — or simply a supplier publishing one — would remove an ambiguity that currently sits underneath every claim made for this compound.
3. Nobody has measured whether it crosses skin. Not one permeation study exists for palmitoyl tripeptide-5 in any model. The arithmetic here says it would need roughly a quarter of the applied dose to reach dermis to hit a plausible active concentration; a Franz cell experiment would replace that estimate with a number in a week.
4. Nobody has tested the topical KRFK result on human skin. KRFK applied topically restored normal wound repair in mice Nor 2005. That is a short peptide with a defined mechanism producing a topical effect in a mammal, and no one has taken it to human skin, in scarring or in ageing. The obvious cosmetic peptide to develop is the one the literature actually supports, and the industry developed a different one instead.
5. Nobody has looked for the fingerprint of the claimed mechanism in users. If this ingredient activates TGF-beta at all, treated skin should show a shift toward the contractile fibroblast phenotype Sakai 2003. Suction blister fluid or a 2 mm punch from treated and untreated forearm skin after 12 weeks, stained for alpha-smooth-muscle actin, would be the first direct evidence for or against the mechanism in a person.
Syn-Coll — its own safety story, not its class's
The class safety block on this page is written for injectable repair peptides. This compound’s own risk story is different and it is entirely about the mechanism it claims.
The claimed mechanism is a fibrosis pathway, and that should be stated plainly rather than skipped. Transforming growth factor beta is the central driver of fibroblast activation, collagen deposition and wound contraction; thrombospondin-1 is a major physiological activator of it Crawford 1998, and the activation produces measurable collagen gel contraction and a several-fold rise in active TGF-beta1 Sakai 2003. A product that genuinely did what this one says it does would carry a real question about keloid-prone skin, about active wounds, and about anywhere a scar is already forming. That question is asked on no page selling it.
And the reason not to be alarmed is the same reason to doubt the claim. Nothing in the delivery arithmetic supports a micromolar dermal concentration from a leave-on cosmetic Bos 2000 Choi 2014, and the peptide in the bottle is not the sequence that does the activating Ribeiro 1999. So the honest summary is: the mechanism as advertised would be worth worrying about, the evidence says the mechanism is not operating, and the two statements are the same statement.
Where that reasoning stops applying. Microneedling, radiofrequency and iontophoresis all defeat the stratum corneum on purpose, and a compromised barrier changes delivery by orders of magnitude rather than by percentages. Anybody using this ingredient immediately after a needling session is applying an untested peptide into open dermis, which is a different exposure and a different risk profile from applying it to intact skin — and it is also the condition under which a TGF-beta claim, if true, would matter most. Keloid-prone skin is the group with the most to lose from that combination and the least data about it.
What the tolerability record does and does not establish. Palmitoyl tripeptide-5 has been used in leave-on cosmetics for two decades and appears in ingredient surveys without irritation flags Resende 2021. That is real reassurance about contact irritation at the concentrations used. It says nothing about whether the ingredient does anything, and on this compound the absence of any biological signal is the safety profile and the efficacy problem at the same time.
Sources read for this page
- Ribeiro SM, Poczatek M, Schultz-Cherry S, Villain M, Murphy-Ullrich JE. The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta. J Biol Chem 1999 · PMID 10224129
- Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998 · PMID 9657149
- Nor JE, Dipietro L, Murphy-Ullrich JE, Hynes RO, Lawler J, Polverini PJ. Activation of Latent TGF-beta1 by Thrombospondin-1 is a Major Component of Wound Repair. Oral Biosci Med 2005 · PMID 21822445
- Sakai K, Sumi Y, Muramatsu H, Hata K, Muramatsu T, Ueda M. Thrombospondin-1 promotes fibroblast-mediated collagen gel contraction caused by activation of latent transforming growth factor beta-1. J Dermatol Sci 2003 · PMID 12670720
- CIR Expert Panel (Cosmetic Ingredient Review). Safety Assessment of Palmitoyl Oligopeptides as Used in Cosmetics (scientific literature review). Cosmetic Ingredient Review 2012
- Resende DISP, Ferreira MS, Sousa-Lobo JM, Sousa E, Almeida IF. Usage of Synthetic Peptides in Cosmetics for Sensitive Skin. Pharmaceuticals (Basel) 2021 · PMID 34451799
- Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000 · PMID 10839713
- Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci 2022 · PMID 35302659
- Choi YL, Park EK, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul) 2014 · PMID 25143811
- Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. Int J Cosmet Sci 2009 · PMID 19570099
- Castelletto V, Hamley IW, Perez J, Abezgauz L, Danino D. Self-assembly of palmitoyl lipopeptides used in skin care products. Langmuir 2013 · PMID 23822110
Syn-Coll — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Repair peptides work by promoting angiogenesis — new blood vessel growth — plus fibroblast migration and growth-factor signaling. That is what makes them useful, and it is the entire basis of the one theoretical concern worth naming: angiogenesis is also what a tumor needs to grow beyond a few millimetres.
- There is no evidence these compounds cause or accelerate cancer. There is a mechanistic reason not to run a pro-angiogenic agent systemically with an active or recently treated malignancy, and that reasoning stands without a trial.
- The second predicted issue is more mundane and more likely: they can mask a signal. Something that reduces pain and inflammation around an injury lets you load a tissue that has not finished healing.
What has actually been reported
- Very well tolerated in reported use. Injection-site reactions and transient light-headedness are the common complaints.
- Human data is thin — most of the literature is rodent — so 'well tolerated' here means 'no signal has emerged from a lot of informal use', which is weaker than a clean trial and stronger than nothing.
How to reduce the risk
Same mechanism as the prediction.
- Stop when the thing you were treating has resolved. There is no mechanism here that demands a clock, and equally no reason to keep running a pro-angiogenic signal once the job is done.
- Do not let reduced pain set your training load. The tissue heals on its own timeline whether or not you can feel it. Reloading early on the strength of feeling better is the most common way people turn a good result into a re-injury.
- Get the diagnosis before the peptide. These accelerate healing of things that heal. A tear that needs surgical repair does not become a tear that does not, and the delay costs you.
- One injury, one compound, long enough to judge it. Otherwise you learn nothing transferable for next time.
What it does to your bloodwork
A fact about the assay.
- Nothing routine tracks these directly. The endpoint is the injury, which means your own honest assessment of function is the measurement.
Don't run this if
- Active or recently treated malignancy — the angiogenesis reasoning.
- Any undiagnosed lump or lesion. Find out what it is first.
The honest unknown
- Long-term systemic exposure in humans has never been characterized. The use case is naturally self-limiting — you stop when the injury resolves — which is why this matters less here than it would elsewhere.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Syn-Coll — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
Applied topically, this has no systemic exposure worth speaking of — so there is nothing to interact with anything you take, and no blood marker it could move. That is the honest answer rather than an empty section. The real interactions for a topical are layering ones: what you put on before and after it, and at what pH.
- How to work up to it, and when not to
- When to take it, and why that window
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Syn-Coll in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Syn-Coll
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| hs-CRP (High-Sensitivity C-Reactive Protein) | Baseline inflammation — the thing you're claiming to reduce |
| Complete Blood Count (CBC) with Differential | Infection, anemia and platelet count before anything injectable |
| Comprehensive Metabolic Panel (CMP) | Liver and kidney baseline |
| Vitamin D (25-Hydroxy) | Low D slows soft-tissue and bone healing measurably |
The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.
Check results you already have → · All 103 markers A–Z
Syn-Coll — frequently asked questions
What is Syn-Coll?
Syn-Coll (Palmitoyl Tripeptide-5) is a healing & recovery research compound. TGF-beta-mimetic lipopeptide — triggers collagen I/III synthesis in dermal fibroblasts.
Is the full Syn-Coll protocol on this page?
The reported research dose is on this page, along with how Syn-Coll works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Syn-Coll?
Syn-Coll has an approximate half-life of N/A (topical), which is part of what determines how often it's dosed.
What's the evidence behind Syn-Coll?
Current evidence level: Cosmetic/topical. Syn-Coll is offered for research purposes only and is not an approved medicine.
What Syn-Coll is used for
Syn-Coll appears under 1 goal in the goal router.
Related Healing & Recovery compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.